Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 08, 2026 1 hour, 38 minutes ago
Medical News: Researchers have uncovered a major immune system difference that may explain why some head and neck cancers linked to the human papillomavirus (HPV) tend to have better survival rates than those caused by smoking or alcohol. The discovery centers on a special group of immune cells known as natural killer cells, or NK cells, which act as the body’s rapid-response defenders against cancer.
Scientists from multiple institutions including the Department of Neurosurgery at Shenzhen Third People’s Hospital and the Second Hospital Affiliated to Southern University of Science and Technology in China, the National Clinical Research Center for Infectious Diseases and Institute for Hepatology at the Third People’s Hospital of Shenzhen, the First Affiliated Hospital of Harbin Medical University and the School of Stomatology at Harbin Medical University, and the Biotherapy Clinical Research Center at Shenzhen Third People’s Hospital conducted the study. Tissue samples used for validation were also obtained from patients undergoing surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences Shenzhen Hospital.
Why HPV-Related Cancers Often Have Better Outcomes
Head and neck squamous cell carcinoma is one of the most common cancers globally. While many cases are linked to tobacco and alcohol use, a growing number are caused by HPV infection. Interestingly, patients with HPV-positive tumors often survive longer than those with HPV-negative tumors. Scientists have long suspected that the immune system plays a role, but the exact mechanism remained unclear.
In this
Medical News report, researchers focused on NK cells inside tumors. These immune cells are part of the body’s innate defense system and can destroy abnormal cells without needing prior exposure to them.
Using advanced single-cell genetic analysis, the team studied immune cells from 28 head and neck cancer patients. Ten had HPV-positive tumors and eighteen had HPV-negative disease. The researchers analyzed more than sixty-four thousand immune cells collected from tumor tissue to understand how NK cells behave in each cancer type.
Four Distinct Types of NK Cells Identified
The investigation revealed that NK cells in these cancers fall into four main groups: adaptive NK cells, cell-killing NK cells, CD56bright NK cells, and virus-responsive NK cells. Each group plays a slightly different role in the immune response.
One particular subset stood out in HPV-positive tumors. These cells, known as CX3CR1-positive KLRB1-low NK cells, showed strong cancer-killing activity and were strongly associated with longer patient survival. They appear to be drawn into tumors by a signaling molecule called CX3CL1, allowing them to attack cancer cells more efficiently.
By contrast, HPV-negative tumors used a different strategy. These cancers produced high levels of molecules called CLEC2C and CLEC2D. These molecules interact with the KLRB1 receptor on NK cells, effectively switching off their ability to kill tumor cells. This immune-blocking pathway allows the cancer to evade the body’s natural defenses.<
br />
Laboratory Validation Confirms Immune Suppression
To confirm the findings, researchers performed immunohistochemistry testing on additional tumor samples. The results showed that HPV-negative tumors indeed produced higher levels of the CLEC2 proteins that suppress NK cell activity.
Patients whose tumors expressed high levels of these inhibitory signals tended to have poorer survival outcomes. This evidence suggests that blocking this immune-escape pathway could become a future treatment strategy.
Conclusions
The study provides strong evidence that HPV status fundamentally shapes how the immune system interacts with head and neck tumors. HPV-positive cancers appear to recruit highly active NK cells capable of attacking tumors effectively, while HPV-negative cancers actively suppress NK cell function through specific inhibitory signals. Understanding these differences opens the door to new personalized immunotherapies that either boost protective NK cell populations or block the suppressive CLEC2–KLRB1 pathway. With further clinical validation, these immune markers could help doctors predict patient outcomes and guide more targeted treatments for head and neck cancer.
The study findings were published in the peer reviewed journal: Cancers.
https://www.mdpi.com/2072-6694/18/5/845
For the latest on HPV and cancer, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/stds
https://www.thailandmedical.news/articles/cancer
Share
Tweet
Share
